drugset / Trial / NCT00691522
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days
Timeline
- Start
- 2008-11
- Primary completion
- 2009-08
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xerecept | Unknown | 1 mg | Subcutaneous |
| Subject | Xerecept | Unknown | 1.5 mg | Subcutaneous |